Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

LIVN vs GKOS vs NVCR vs TNDM vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
LIVN
LivaNova PLC

Medical - Devices

HealthcareNASDAQ • GB
Market Cap$3.88B
5Y Perf.+32.6%
GKOS
Glaukos Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$7.85B
5Y Perf.+244.2%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-75.0%
TNDM
Tandem Diabetes Care, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$1.27B
5Y Perf.-77.8%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$99.94B
5Y Perf.-20.9%

LIVN vs GKOS vs NVCR vs TNDM vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
LIVN logoLIVN
GKOS logoGKOS
NVCR logoNVCR
TNDM logoTNDM
MDT logoMDT
IndustryMedical - DevicesMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesMedical - Devices
Market Cap$3.88B$7.85B$1.92B$1.27B$99.94B
Revenue (TTM)$1.43B$551M$674M$1.03B$35.48B
Net Income (TTM)$107M$-189M$-173M$-95M$4.61B
Gross Margin67.5%78.1%75.2%54.9%61.9%
Operating Margin13.4%-15.6%-27.2%-7.9%17.9%
Forward P/E16.8x14.1x
Total Debt$473M$140M$290M$444M$28.52B
Cash & Equiv.$636M$91M$103M$91M$2.22B

LIVN vs GKOS vs NVCR vs TNDM vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

LIVN
GKOS
NVCR
TNDM
MDT
StockMay 20May 26Return
LivaNova PLC (LIVN)100132.6+32.6%
Glaukos Corporation (GKOS)100344.2+244.2%
NovoCure Limited (NVCR)10025.0-75.0%
Tandem Diabetes Car… (TNDM)10022.2-77.8%
Medtronic plc (MDT)10079.1-20.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: LIVN vs GKOS vs NVCR vs TNDM vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 5 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. LivaNova PLC is the stronger pick specifically for recent price momentum and sentiment. GKOS also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
LIVN
LivaNova PLC
The Momentum Pick

LIVN is the #2 pick in this set and the best alternative if momentum is your priority.

  • +63.0% vs TNDM's -17.0%
Best for: momentum
GKOS
Glaukos Corporation
The Growth Play

GKOS ranks third and is worth considering specifically for growth exposure and long-term compounding.

  • Rev growth 32.3%, EPS growth -18.4%, 3Y rev CAGR 21.5%
  • 457.1% 10Y total return vs LIVN's 46.2%
  • Lower volatility, beta 1.20, Low D/E 21.3%, current ratio 4.69x
  • Beta 1.20, current ratio 4.69x
Best for: growth exposure and long-term compounding
NVCR
NovoCure Limited
The Healthcare Pick

NVCR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
TNDM
Tandem Diabetes Care, Inc.
The Healthcare Pick

Among these 5 stocks, TNDM doesn't own a clear edge in any measured category.

Best for: healthcare exposure
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 36 yrs, beta 0.47, yield 3.6%
  • Better valuation composite
  • 13.0% margin vs GKOS's -34.3%
  • Beta 0.47 vs NVCR's 2.20, lower leverage
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthGKOS logoGKOS32.3% revenue growth vs MDT's 3.6%
ValueMDT logoMDTBetter valuation composite
Quality / MarginsMDT logoMDT13.0% margin vs GKOS's -34.3%
Stability / SafetyMDT logoMDTBeta 0.47 vs NVCR's 2.20, lower leverage
DividendsMDT logoMDT3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)LIVN logoLIVN+63.0% vs TNDM's -17.0%
Efficiency (ROA)MDT logoMDT175.8% ROA vs GKOS's -20.1%, ROIC 6.0% vs -9.2%

LIVN vs GKOS vs NVCR vs TNDM vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

LIVNLivaNova PLC
FY 2025
Cardiopulmonary Segment
57.0%$785M
Neuromodulation Segment
43.0%$593M
GKOSGlaukos Corporation
FY 2019
Glaucoma
97.5%$231M
Corneal Health
2.5%$6M
NVCRNovoCure Limited

Segment breakdown not available.

TNDMTandem Diabetes Care, Inc.
FY 2025
Supplies and Other
54.3%$551M
Pump
45.7%$464M
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

LIVN vs GKOS vs NVCR vs TNDM vs MDT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMDTLAGGINGTNDM

Income & Cash Flow (Last 12 Months)

MDT leads this category, winning 3 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 64.4x GKOS's $551M. MDT is the more profitable business, keeping 13.0% of every revenue dollar as net income compared to GKOS's -34.3%. On growth, GKOS holds the edge at +41.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricLIVN logoLIVNLivaNova PLCGKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
RevenueTrailing 12 months$1.4B$551M$674M$1.0B$35.5B
EBITDAEarnings before interest/tax$220M-$40M-$165M-$68M$9.4B
Net IncomeAfter-tax profit$107M-$189M-$173M-$95M$4.6B
Free Cash FlowCash after capex$161M-$18M-$48M-$4M$5.4B
Gross MarginGross profit ÷ Revenue+67.5%+78.1%+75.2%+54.9%+61.9%
Operating MarginEBIT ÷ Revenue+13.4%-15.6%-27.2%-7.9%+17.9%
Net MarginNet income ÷ Revenue+7.5%-34.3%-25.7%-9.2%+13.0%
FCF MarginFCF ÷ Revenue+11.2%-3.4%-7.1%-0.4%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year+14.3%+41.2%+12.3%+5.5%+8.8%
EPS Growth (YoY)Latest quarter vs prior year+106.7%-6.3%-100.0%+84.8%-11.9%
MDT leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 4 of 6 comparable metrics.

On an enterprise value basis, MDT's 14.3x EV/EBITDA is more attractive than LIVN's 15.4x.

MetricLIVN logoLIVNLivaNova PLCGKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
Market CapShares × price$3.9B$7.9B$1.9B$1.3B$99.9B
Enterprise ValueMkt cap + debt − cash$3.7B$7.9B$2.1B$1.6B$126.2B
Trailing P/EPrice ÷ TTM EPS-15.94x-40.90x-13.80x-6.08x21.60x
Forward P/EPrice ÷ next-FY EPS est.16.84x14.13x
PEG RatioP/E ÷ EPS growth rate36.00x
EV / EBITDAEnterprise value multiple15.40x14.32x
Price / SalesMarket cap ÷ Revenue2.79x15.47x2.92x1.25x2.98x
Price / BookPrice ÷ Book value/share3.22x11.69x5.51x8.01x2.08x
Price / FCFMarket cap ÷ FCF22.40x19.28x
MDT leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

MDT leads this category, winning 4 of 9 comparable metrics.

MDT delivers a 9.4% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-68 for TNDM. GKOS carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to TNDM's 2.86x. On the Piotroski fundamental quality scale (0–9), MDT scores 6/9 vs TNDM's 3/9, reflecting solid financial health.

MetricLIVN logoLIVNLivaNova PLCGKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
ROE (TTM)Return on equity+9.1%-26.5%-50.8%-68.3%+9.4%
ROA (TTM)Return on assets+4.2%-20.1%-16.5%-10.0%+175.8%
ROICReturn on invested capital+11.5%-9.2%-16.4%-10.0%+6.0%
ROCEReturn on capital employed+10.2%-10.3%-28.9%-11.5%+7.5%
Piotroski ScoreFundamental quality 0–953536
Debt / EquityFinancial leverage0.39x0.21x0.85x2.86x0.59x
Net DebtTotal debt minus cash-$162M$49M$187M$354M$26.3B
Cash & Equiv.Liquid assets$636M$91M$103M$91M$2.2B
Total DebtShort + long-term debt$473M$140M$290M$444M$28.5B
Interest CoverageEBIT ÷ Interest expense3.98x-18.69x-96.80x-15.99x9.08x
MDT leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

GKOS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in GKOS five years ago would be worth $16,155 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, LIVN leads with a +63.0% total return vs TNDM's -17.0%. The 3-year compound annual growth rate (CAGR) favors GKOS at 31.7% vs NVCR's -37.6% — a key indicator of consistent wealth creation.

MetricLIVN logoLIVNLivaNova PLCGKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
YTD ReturnYear-to-date+17.0%+21.2%+28.3%-14.3%-18.1%
1-Year ReturnPast 12 months+63.0%+52.0%+1.1%-17.0%-2.8%
3-Year ReturnCumulative with dividends+50.5%+128.7%-75.7%-44.8%-4.2%
5-Year ReturnCumulative with dividends-14.5%+61.5%-91.3%-78.0%-27.7%
10-Year ReturnCumulative with dividends+46.2%+457.1%+30.3%-75.4%+26.5%
CAGR (3Y)Annualised 3-year return+14.6%+31.7%-37.6%-18.0%-1.4%
GKOS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — LIVN and MDT each lead in 1 of 2 comparable metrics.

MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.6% from its 52-week high vs TNDM's 62.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricLIVN logoLIVNLivaNova PLCGKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5001.29x1.20x2.20x1.45x0.47x
52-Week HighHighest price in past year$71.92$146.75$20.06$29.65$106.33
52-Week LowLowest price in past year$39.36$73.16$9.82$9.98$77.16
% of 52W HighCurrent price vs 52-week peak+98.6%+91.4%+83.9%+62.3%+73.3%
RSI (14)Momentum oscillator 0–10057.663.069.839.127.3
Avg Volume (50D)Average daily shares traded808K678K1.5M1.8M7.8M
Evenly matched — LIVN and MDT each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: LIVN as "Buy", GKOS as "Buy", NVCR as "Buy", TNDM as "Buy", MDT as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 7.0% for LIVN (target: $76). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.

MetricLIVN logoLIVNLivaNova PLCGKOS logoGKOSGlaukos Corporati…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…MDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$75.88$146.67$33.50$31.62$109.50
# AnalystsCovering analysts1424153949
Dividend YieldAnnual dividend ÷ price+3.6%
Dividend StreakConsecutive years of raises36
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap+0.1%0.0%0.0%0.0%+3.2%
Insufficient data to determine a leader in this category.
Key Takeaway

MDT leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). GKOS leads in 1 (Total Returns). 1 tied.

Best OverallMedtronic plc (MDT)Leads 3 of 6 categories
Loading custom metrics...

LIVN vs GKOS vs NVCR vs TNDM vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is LIVN or GKOS or NVCR or TNDM or MDT a better buy right now?

For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.

3% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate LivaNova PLC (LIVN) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — LIVN or GKOS or NVCR or TNDM or MDT?

On forward P/E, Medtronic plc is actually cheaper at 14.

1x.

03

Which is the better long-term investment — LIVN or GKOS or NVCR or TNDM or MDT?

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +61.

5%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: GKOS returned +457. 1% versus TNDM's -75. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — LIVN or GKOS or NVCR or TNDM or MDT?

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 373% more volatile than MDT relative to the S&P 500. On balance sheet safety, Glaukos Corporation (GKOS) carries a lower debt/equity ratio of 21% versus 3% for Tandem Diabetes Care, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — LIVN or GKOS or NVCR or TNDM or MDT?

By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.

3% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, GKOS leads at 21. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — LIVN or GKOS or NVCR or TNDM or MDT?

Medtronic plc (MDT) is the more profitable company, earning 13.

9% net margin versus -37. 0% for Glaukos Corporation — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — GKOS leads at 77. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is LIVN or GKOS or NVCR or TNDM or MDT more undervalued right now?

On forward earnings alone, Medtronic plc (MDT) trades at 14.

1x forward P/E versus 16. 8x for LivaNova PLC — 2. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

08

Which pays a better dividend — LIVN or GKOS or NVCR or TNDM or MDT?

In this comparison, MDT (3.

6% yield) pays a dividend. LIVN, GKOS, NVCR, TNDM do not pay a meaningful dividend and should not be held primarily for income.

09

Is LIVN or GKOS or NVCR or TNDM or MDT better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between LIVN and GKOS and NVCR and TNDM and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LIVN is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; TNDM is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while LIVN, GKOS, NVCR, TNDM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

LIVN

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 5%
Run This Screen
Stocks Like

GKOS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 20%
  • Gross Margin > 46%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

TNDM

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 32%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform LIVN and GKOS and NVCR and TNDM and MDT on the metrics below

Revenue Growth>
%
(LIVN: 14.3% · GKOS: 41.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.